Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Make your choice for the bird that catches your heart! - 2Find Your Ideal Tea: Six Particular Assortments
- 3Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- 4American Airlines Flight Attendant Disappears Amid Layover in Colombia, Authorities Investigating
- 5A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns
- Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- Islamic State group militants claim capture and execution of a Nigerian brigadier general
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- A Concise History Of The Entertainment world
- How to disinfect if the stomach bug hits your home
- Fiber is something most people could use more of. But experts advise caution with 'fibermaxxing'
- European nations criticise Israel’s death penalty plans
